SYDNEY, Dec. 11 (Xinhua) -- An Australian COVID-19 vaccine under development by the University of Queensland (UQ) and local biotech firm CSL will not progress to Phase 2/3 trials after returning false positive HIV test results.
Relevant parties announced Friday that despite eliciting an effective virus response and strong safety profile, a deal for the Australian Government to purchase over 50 million doses of the vaccine had been cancelled.
UQ and CSL stressed there was no possibility the vaccine causes HIV infection and that 216 people involved in the trial experienced no serious adverse health effects.
However, due to the implications of delivering the vaccine to the broader populations and potential interference with existing HIV testing procedures, CSL and the Australian Government agreed vaccine development would not proceed to Phase 2/3 trials.
Chief Scientific Officer for CSL Dr Andrew Nash said the outcome "highlights the risk of failure associated with early vaccine development."
CSL will continue with plans to manufacture approximately 30 million doses of the Oxford/AstraZeneca vaccine candidate with first doses planned for release in Australia early 2021.
Following the failure of the UQ vaccine, the Australian government revealed it would commission the manufacture of additional 20 million doses of the Oxford/AstraZeneca and increase access to the U.S. Novavax vaccine to around 50 million doses.
Australian Prime Minister Scott Morrison said it was no surprise that not all vaccine candidates made it through the trial process and that a commitment to safety and health was central to the Government's response.
"I do want to thank, though, Professor Paul Young and all the team up there at University of Queensland for the amazing work that they have done in getting the vaccine to that stage," Morrison said.
"We will continue to support and fund the work that they're doing on molecular clamp research on vaccines, which has application in many other areas." Enditem